Kaleido Biosciences Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
As previously announced, the meeting will be held on
Attending the Virtual Annual Meeting
As described in the proxy materials for the Annual Meeting, Stockholders of record and beneficial owners as of the close of business on
As part of the registration process, Stockholders will be required to enter the control number that appears on their proxy card, voter instruction form, notice of internet availability of proxy materials, or previously received email. Beneficial owners must obtain a legally valid proxy from their broker, bank or other agent and provide this proxy during the registration process. After completing registration, Stockholders and beneficial owners will receive further instructions via email, including unique links to the website where they can access the Annual Meeting and vote online during the meeting.
Participants are encouraged to access the Annual Meeting prior to the start time. Stockholders of record and beneficial owners needing technical support will be able to access support during registration and on the day of the meeting.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Chief Financial Officer
Source: Kaleido Biosciences